When a doctor tells you that you have "fatty liver," the medical term they're using is hepatic steatosis. Defined histologically as the accumulation of triglycerides in more than 5% of hepatocytes, it is the most common chronic liver disease worldwide — affecting an estimated 30–38% of the global adult population (Rinella et al., 2023).
In most people, hepatic steatosis causes no symptoms. It is commonly discovered incidentally: on an ultrasound ordered for another reason, or through mildly elevated liver enzymes on routine blood work. This silence is deceptive. Left unaddressed — particularly in the presence of metabolic risk factors — steatosis can progress through steatohepatitis, fibrosis, and eventually cirrhosis. The good news is that of all the stages of chronic liver disease, simple steatosis is among the most reversible.
This guide covers what hepatic steatosis is, how it differs from MASLD and NASH, how each diagnostic test detects and grades it, and what your results concretely mean.
What Is Hepatic Steatosis?
The liver is normally a lean organ. Healthy hepatocytes (liver cells) contain very little fat. Steatosis occurs when fat — primarily in the form of triglycerides — begins to accumulate within hepatocytes as lipid droplets visible under a microscope. The histological threshold for diagnosis is when more than 5% of hepatocytes contain these visible fat droplets.
Depending on the underlying cause, steatosis is classified into two main categories:
| Type | Old Name | Current Name | Key Cause |
|---|---|---|---|
| Metabolic steatosis | NAFLD / NASH | MASLD / MASH | Insulin resistance, obesity, T2DM, dyslipidaemia |
| Alcohol-related steatosis | ALD / AFLD | MetALD / ALD | Excessive alcohol consumption |
| Drug-induced steatosis | DILI (steatotic) | DILI (steatotic) | Amiodarone, methotrexate, tamoxifen, steroids |
| Other/rare causes | — | — | Wilson's disease, lipodystrophy, TPN |
In 2023, an international nomenclature consensus replaced "NAFLD" with MASLD (metabolic dysfunction-associated steatotic liver disease). MASLD requires steatosis plus at least one of five cardiometabolic risk factors: overweight/obesity, type 2 diabetes, hypertension, hypertriglyceridaemia, or low HDL-cholesterol (Rinella et al., 2023).
The MASLD Spectrum: From Steatosis to Cirrhosis
Hepatic steatosis is the first and most benign rung of the MASLD ladder. Understanding the full spectrum helps you put your diagnosis in context:
| Stage | What It Means | Fibrosis Stage | Risk of Progression |
|---|---|---|---|
| Simple steatosis | Fat in >5% hepatocytes; no inflammation or ballooning | F0 | Low (~1–2%/year to MASH) |
| MASH (steatohepatitis) | Fat + inflammation + hepatocyte ballooning | F0–F4 | Moderate; drives fibrosis progression |
| Significant fibrosis | Scar tissue replacing normal liver cells | F2–F3 | High mortality risk without intervention |
| Cirrhosis | Extensive scarring; loss of normal liver architecture | F4 | HCC and decompensation risk |
How Hepatic Steatosis Is Diagnosed
There is no single blood test that reliably detects steatosis. ALT may be mildly elevated (or even normal in up to 40–80% of MASLD patients), and the finding of steatosis typically requires imaging confirmation. The diagnostic pathway usually moves from readily available tests toward more specialised ones.
Blood Tests: What They Can and Can't Tell You
Liver enzymes, particularly ALT, are often the first clue. Optimised ALT cutoffs for detecting steatosis are lower than traditional laboratory reference ranges: 30 U/L for men and 19 U/L for women (Prati et al., 2002). However, a normal ALT does not rule out steatosis or even significant fibrosis. GGT may also be elevated and tracks strongly with insulin resistance and BMI. Neither enzyme directly quantifies how much fat is present.
Abdominal Ultrasound: First-Line Imaging
Ultrasound is the most commonly used first-line test for steatosis because it is non-invasive, inexpensive, widely available, and carries no radiation exposure. When fat accumulates in hepatocytes, it reflects ultrasound waves differently — the liver appears abnormally bright (hyperechoic) compared to the right kidney. Sonographers look for five key features:
| Sonographic Sign | What It Looks Like | Clinical Significance |
|---|---|---|
| Increased echogenicity ("bright liver") | Liver parenchyma appears brighter than normal | Hallmark finding; severity correlates with fat content |
| Hepatorenal contrast | Liver noticeably brighter than adjacent right kidney | Most reliable comparative sign; HRI ≥1.49 = 87% sensitivity, 89% specificity |
| Vascular blunting | Portal vein walls become progressively less visible | Suggests moderate-to-severe steatosis |
| Deep beam attenuation | Poor visualisation of the posterior right liver lobe | More prominent in severe steatosis |
| Surface nodularity | Irregular liver surface on higher-frequency imaging | Suggests advanced fibrosis/cirrhosis rather than steatosis alone |
Ultrasound grades steatosis from Grade 0 (normal) to Grade 3 (severe, with deep attenuation and loss of vascular landmarks). However, conventional B-mode ultrasound has a significant limitation: it cannot reliably detect mild steatosis (below ~20–33% hepatic fat fraction) and is operator-dependent. For quantitative assessment, advanced techniques are available.
FibroScan CAP: Quantitative Fat Grading
FibroScan machines equipped with CAP (Controlled Attenuation Parameter) can simultaneously measure liver stiffness (for fibrosis) and fat content (for steatosis). CAP is reported in dB/m and reflects how much the ultrasound signal is attenuated by hepatic fat:
| CAP Score (dB/m) | Steatosis Grade | Fat Fraction (approx.) | Clinical Interpretation |
|---|---|---|---|
| < 238 | S0 — Minimal/None | < 5% | Normal hepatic fat content |
| 238–259 | S1 — Mild | 5–33% | Mild steatosis; monitor metabolic risk factors |
| 260–292 | S2 — Moderate | 34–66% | Moderate steatosis; lifestyle intervention indicated |
| > 292 | S3 — Severe | > 67% | Severe steatosis; increased risk of MASH and fibrosis |
MRI-PDFF: The Reference Standard
For the most accurate non-invasive quantification of hepatic fat, MRI-PDFF (proton density fat fraction) is the current gold standard. It measures the fraction of tissue that is fat across the entire liver volume, unaffected by BMI, and provides a continuous percentage rather than a categorical grade. Thresholds: PDFF ≥5% confirms steatosis; ≥17–20% is associated with a higher likelihood of steatohepatitis. MRI-PDFF is particularly useful in research settings, when clinical decisions depend on precise fat quantification, and in patients where FibroScan quality is suboptimal (morbid obesity, narrow intercostal spaces).
What Blood Tests Accompany a Steatosis Diagnosis?
While blood tests can't directly measure fat in the liver, several values from a standard panel provide important context alongside imaging findings:
| Test | What to Look For in Steatosis | Why It Matters |
|---|---|---|
| ALT (SGPT) | Often mildly elevated (1–3× ULN) but can be normal | Marker of hepatocellular injury; optimised cutoff: 30 (M) / 19 (F) U/L |
| AST (SGOT) | Usually lower than ALT in metabolic steatosis (AST/ALT <1) | AST rising above ALT suggests advancing fibrosis or alcohol |
| GGT | Elevated in 50–70% of MASLD patients; correlates with insulin resistance | Sensitive early marker; elevated GGT + ALP = cholestatic pattern |
| Triglycerides | Often elevated (>150 mg/dL); part of MASLD metabolic risk criteria | Directly contributes to hepatic fat accumulation |
| HbA1c / Fasting glucose | Elevated in concurrent diabetes/pre-diabetes | Insulin resistance is a major driver of steatosis severity |
| Platelets | May fall with advancing fibrosis | Used in FIB-4 calculation; thrombocytopenia suggests portal hypertension |
| Albumin / INR | Normal in simple steatosis; impaired only in advanced disease | If abnormal, suggests cirrhosis rather than simple steatosis |
The FIB-4 score, calculated from your age, AST, ALT, and platelet count, is the recommended first-line tool for estimating whether fibrosis has developed on top of steatosis. A low FIB-4 (<1.30) makes advanced fibrosis unlikely; a high FIB-4 (>2.67) warrants referral for elastography.
Is Hepatic Steatosis Reversible?
Simple hepatic steatosis is one of the most reversible conditions in hepatology. The liver has a remarkable capacity for fat clearance when the metabolic drivers are addressed. Evidence from clinical trials and cohort studies shows:
The most evidence-supported interventions for reducing hepatic fat are: sustained caloric restriction (particularly reducing sugar and fructose), structured aerobic and resistance exercise, treatment of underlying insulin resistance and diabetes, and — increasingly — GLP-1 receptor agonists. Vitamin E (800 IU/day) has shown benefit in non-diabetic MASH patients in clinical trials, though long-term safety in men and diabetic patients requires consideration.
Frequently Asked Questions
Hepatic steatosis is the medical term for fatty liver — a condition where more than 5% of hepatocytes (liver cells) contain fat droplets. It affects approximately 30–38% of the global adult population and is most commonly associated with obesity, type 2 diabetes, insulin resistance, and metabolic syndrome. It is the most common chronic liver condition in high-income countries.
Hepatic steatosis is the first stage of MASLD (metabolic dysfunction-associated steatotic liver disease), previously called NAFLD. MASLD requires steatosis plus at least one cardiometabolic risk factor (obesity, type 2 diabetes, hypertension, dyslipidaemia, or insulin resistance). Not all steatosis meets MASLD criteria — for example, alcohol-related or drug-induced steatosis is classified separately. "NASH" has been renamed MASH (metabolic dysfunction-associated steatohepatitis) and refers to steatosis with coexisting inflammation and hepatocyte injury.
On ultrasound, Grade 2 (moderate steatosis) means a moderately increased liver echogenicity with slightly impaired visualisation of the portal vein walls and diaphragm. Conventionally, this corresponds to fat accumulation in roughly 33–66% of hepatocytes. However, B-mode ultrasound grading is subjective and operator-dependent. For more precise quantification, a FibroScan with CAP or MRI-PDFF is recommended, especially if clinical decisions depend on the exact degree of steatosis.
This is actually very common — up to 40–80% of patients with biopsy-proven MASLD have normal ALT levels. Normal enzymes do not mean the liver is unaffected; they simply mean liver cell injury is not currently significant enough to cause enzyme leakage into the bloodstream. What matters more is whether fibrosis has developed, which requires a FIB-4 score and possibly a FibroScan to assess. If your FIB-4 is below 1.30, significant fibrosis is unlikely, and the priority becomes addressing metabolic risk factors to prevent progression.
CAP (Controlled Attenuation Parameter) measures how fat in the liver attenuates ultrasound energy, reported in dB/m. A CAP below 238 dB/m suggests minimal or no steatosis. 238–259 suggests mild steatosis (S1). 260–292 suggests moderate steatosis (S2). Above 292 suggests severe steatosis (S3). These cutoffs vary slightly by probe type (M vs. XL) and should be interpreted alongside the LSM value (liver stiffness for fibrosis) and your clinical picture. See our complete FibroScan guide for detailed interpretation.
In the vast majority of cases, hepatic steatosis alone causes no symptoms. Some patients report mild right upper quadrant discomfort or fatigue, but these are non-specific and frequently unrelated to the liver fat itself. This is why fatty liver is so often discovered incidentally — on an ultrasound ordered for another reason, or through unexpectedly elevated liver enzymes on routine blood work. Symptoms only reliably develop when the disease progresses to steatohepatitis, significant fibrosis, or cirrhosis.
Go Deeper on Fatty Liver Diagnosis
Our in-depth guides cover every imaging technique, blood test, and fibrosis score used in MASLD assessment — backed by current EASL and AASLD guidelines.
Ultrasound Guide FibroScan Deep Dive